🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to researchers.

A Worldwide Public Health Issue

Cases of gonorrhoea are on the rise around the world, with figures suggesting over 82 million new cases annually. Particularly high rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune development in the reality of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs at this time.”

Public health authorities are deeply concerned about the rise in drug-resistant strains. The global health body has classified it as a "high-priority threat". Ongoing monitoring found that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Clearance

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Experts believe that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the pharmaceutical company GSK, also received approval in concurrent days. This treatment, which is also used to treat UTIs, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization signifies a significant shift in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Research Study Results and Global Access

According to findings released by a prominent scientific publication, the new drug successfully treated the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the current standard treatment, which combines two antibiotics. The trial enrolled over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the authority to make available and distribute the drug in a wide range of regions with limited resources.

Medical professionals treating patients have shared positive views. The availability of a single-dose, oral treatment like this is seen as a "game-changer" for gonorrhoea control. This is considered crucial to reduce the burden of the infection for people and to stop the proliferation of highly drug-resistant gonorrhoea globally.